#JPM24 quick hits: Ionis on partnership’s pros and cons; Novo Ventures has $600M to spend; Are small molecules back? + more

SAN FRANCISCO — The biopharma extravaganza that is the JP Morgan Healthcare Conference started to wind down Wednesday. Here’s what we’re hearing on Wednesday around San Francisco:

Ionis is ready to go solo — After 35 years in the drug development world, the antisense biotech is itching to market its…
Click here to view original post